These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6615095)

  • 1. Comparative in vitro activities of third-generation cephalosporins.
    Fass RJ
    Arch Intern Med; 1983 Sep; 143(9):1743-5. PubMed ID: 6615095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antibacterial activity of eight third generation cephalosporins (author's transl)].
    Deforges L; Le Van Thoi J; Soussy CJ; Duval J
    Pathol Biol (Paris); 1982 Jun; 30(6):363-9. PubMed ID: 6810282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
    Lim VK; Halijah MY
    Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
    Bell JM; Turnidge JD;
    Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activity of new beta-lactam antibiotics].
    Cullmann W; Stieglitz M
    Fortschr Med; 1982 May; 100(19):888-92. PubMed ID: 6807788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.
    Fass RJ
    Arch Intern Med; 1980 Jun; 140(6):763-8. PubMed ID: 7387270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefotaxime against enterococci.
    Moellering RC; Eliopoulos GM
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):85S-90S. PubMed ID: 6086221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In-vitro activity of ceftriaxone on Gram-negative bacilli with various resistance phenotypes to cephalosporins. Comparison with cefotaxime, cefmenoxime, moxalactam, ceftazidime].
    Rouhan D; Le Noc P; Le Noc D
    Pathol Biol (Paris); 1986 May; 34(5):404-9. PubMed ID: 3534713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria.
    Thornsberry C
    Am J Med; 1985 Aug; 79(2A):14-20. PubMed ID: 3927723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro sensitivity of strict anaerobic Gram-negative bacilli to thienamycin NF and various cephalosporins].
    Dubreuil L; Devos J; Romond C
    Pathol Biol (Paris); 1984 May; 32(5):429-32. PubMed ID: 6739150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity of cefmenoxime (SCE 1365) against 616 hospital strains of gram-negative bacilli chosen for beta-lactam resistance. Comparison with cefotaxime, lamoxactam and ceftazidime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1983 May; 31(5):351-6. PubMed ID: 6312396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
    Downs JT; Andriole VT
    Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO; Bryskier A; Izard D; Leclerc H
    Pathol Biol (Paris); 1983 May; 31(5):347-50. PubMed ID: 6312395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM; Guenthner SH; Wenzel RP
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.